21.53

1.01% -0.22

Sarepta Therapeutics Inc (SRPT)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché SRPT Giù? Forum Previsione Frazionamento azionario

Precedente Chiudi:

$21.75

Aprire:

$21.72

Volume 24 ore:

2.01M

Relative Volume:

0.38

Capitalizzazione di mercato:

$2.26B

Reddito:

$2.48B

Utile/perdita netta:

$-57.96M

Rapporto P/E:

-28.38

EPS:

-0.7585

Flusso di cassa netto:

$-453.97M

1 W Prestazione:

-3.28%

1M Prestazione:

+19.61%

6M Prestazione:

-42.29%

1 anno Prestazione:

-82.70%

Intervallo 1D:

$21.18

$21.74

Intervallo di 1 settimana:

$20.76

$22.85

Portata 52W:

$10.41

$129.84

Sarepta Therapeutics Inc Stock (SRPT) Company Profile

Nome

Sarepta Therapeutics Inc

Settore

Healthcare (1123)

Industria

Biotechnology (627)

Telefono

617-274-4000

Indirizzo

215 FIRST STREET, CAMBRIDGE, MA

Dipendente

1,372

Cinguettio

@sarepta

Prossima data di guadagno

2025-08-01

Ultimi documenti SEC

SRPT's Discussions on Twitter

Confronta SRPT con altri titoli

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
SRPT Sarepta Therapeutics Inc	21.53	2.28B	2.48B	-57.96M	-453.97M	-0.7585
VRTX Vertex Pharmaceuticals Inc	452.04	113.14B	11.74B	3.68B	3.34B	14.19
REGN Regeneron Pharmaceuticals Inc	741.29	78.49B	14.25B	4.58B	3.88B	41.77
ARGX Argen X Se Adr	877.94	54.76B	3.06B	1.28B	447.35M	19.67
ALNY Alnylam Pharmaceuticals Inc	397.55	54.51B	3.21B	43.57M	221.36M	0.2405
INSM Insmed Inc	197.01	41.64B	447.02M	-1.18B	-906.14M	-6.1812

Sarepta Therapeutics Inc Stock (SRPT) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2025-12-09	Iniziato	Wedbush	Outperform
2025-11-05	Aggiornamento	Mizuho	Neutral → Outperform
2025-09-22	Aggiornamento	BMO Capital Markets	Market Perform → Outperform
2025-07-29	Aggiornamento	Barclays	Underweight → Equal Weight
2025-07-29	Iniziato	Bernstein	Mkt Perform
2025-07-29	Reiterato	H.C. Wainwright	Sell
2025-07-29	Aggiornamento	JP Morgan	Underweight → Neutral
2025-07-29	Aggiornamento	Oppenheimer	Perform → Outperform
2025-07-28	Downgrade	Barclays	Equal Weight → Underweight
2025-07-25	Downgrade	JP Morgan	Neutral → Underweight
2025-07-24	Iniziato	Citigroup	Sell
2025-07-23	Downgrade	BofA Securities	Neutral → Underperform
2025-07-22	Downgrade	Barclays	Overweight → Equal Weight
2025-07-21	Downgrade	Deutsche Bank	Buy → Hold
2025-07-21	Downgrade	Leerink Partners	Outperform → Market Perform
2025-07-21	Downgrade	Mizuho	Outperform → Neutral
2025-07-21	Downgrade	Needham	Hold → Underperform
2025-07-21	Downgrade	UBS	Buy → Neutral
2025-07-18	Downgrade	Needham	Buy → Hold
2025-06-20	Downgrade	William Blair	Outperform → Mkt Perform
2025-06-18	Downgrade	TD Cowen	Buy → Hold
2025-06-17	Iniziato	Wolfe Research	Peer Perform
2025-06-16	Downgrade	BMO Capital Markets	Outperform → Market Perform
2025-06-16	Downgrade	BofA Securities	Buy → Neutral
2025-06-16	Downgrade	Cantor Fitzgerald	Overweight → Neutral
2025-06-16	Downgrade	H.C. Wainwright	Neutral → Sell
2025-06-16	Downgrade	Morgan Stanley	Overweight → Equal-Weight
2025-06-16	Downgrade	Piper Sandler	Overweight → Neutral
2025-06-06	Aggiornamento	Scotiabank	Sector Perform → Sector Outperform
2025-05-08	Downgrade	Evercore ISI	Outperform → In-line
2025-04-11	Iniziato	Wells Fargo	Overweight
2025-04-02	Aggiornamento	H.C. Wainwright	Sell → Neutral
2025-03-31	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
2025-02-11	Iniziato	Deutsche Bank	Hold
2024-11-27	Reiterato	Needham	Buy
2024-11-25	Iniziato	H.C. Wainwright	Sell
2024-11-07	Aggiornamento	Cantor Fitzgerald	Neutral → Overweight
2024-10-21	Iniziato	Jefferies	Buy
2024-10-10	Ripresa	Raymond James	Outperform
2024-07-29	Aggiornamento	RBC Capital Mkts	Sector Perform → Outperform
2024-06-26	Downgrade	Citigroup	Buy → Neutral
2024-05-31	Iniziato	Piper Sandler	Overweight
2024-05-28	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
2024-05-14	Aggiornamento	Oppenheimer	Perform → Outperform
2024-01-31	Iniziato	BMO Capital Markets	Outperform
2023-12-13	Ripresa	Citigroup	Buy
2023-12-12	Iniziato	Deutsche Bank	Buy
2023-11-21	Iniziato	Wedbush	Outperform
2023-10-31	Downgrade	Cantor Fitzgerald	Overweight → Neutral
2023-10-31	Downgrade	Oppenheimer	Outperform → Perform
2023-06-23	Downgrade	Evercore ISI	Outperform → In-line
2023-04-26	Iniziato	SMBC Nikko	Outperform
2023-04-04	Iniziato	Citigroup	Buy
2023-03-01	Aggiornamento	Morgan Stanley	Equal-Weight → Overweight
2022-12-22	Reiterato	BTIG Research	Buy
2022-12-16	Aggiornamento	UBS	Neutral → Buy
2022-04-04	Ripresa	Cantor Fitzgerald	Overweight
2022-01-05	Reiterato	Needham	Buy
2021-12-09	Aggiornamento	Oppenheimer	Perform → Outperform
2021-11-05	Aggiornamento	JP Morgan	Neutral → Overweight
2021-09-15	Aggiornamento	Guggenheim	Neutral → Buy
2021-08-05	Aggiornamento	JP Morgan	Underweight → Neutral
2021-06-15	Iniziato	BTIG Research	Buy
2021-04-26	Ripresa	Credit Suisse	Neutral
2021-01-12	Downgrade	Citigroup	Buy → Neutral
2021-01-11	Downgrade	UBS	Buy → Neutral
2021-01-08	Downgrade	JP Morgan	Overweight → Underweight
2021-01-08	Downgrade	Morgan Stanley	Overweight → Equal-Weight
2021-01-08	Downgrade	Raymond James	Outperform → Mkt Perform
2020-11-11	Iniziato	Berenberg	Hold
2020-10-28	Iniziato	UBS	Buy
2020-08-25	Iniziato	Raymond James	Outperform
2020-08-20	Downgrade	Credit Suisse	Outperform → Neutral
2020-03-31	Iniziato	Mizuho	Buy
2019-11-01	Iniziato	Guggenheim	Buy
2019-08-21	Reiterato	Needham	Buy
2019-07-09	Reiterato	Morgan Stanley	Overweight
2019-07-01	Reiterato	RBC Capital Mkts	Outperform
2019-04-12	Iniziato	Evercore ISI	Outperform
2019-03-11	Reiterato	Credit Suisse	Outperform
2018-10-12	Iniziato	Bernstein	Outperform
2018-10-01	Iniziato	Cantor Fitzgerald	Overweight
2018-09-26	Reiterato	RBC Capital Mkts	Outperform
2018-09-14	Ripresa	BofA/Merrill	Buy
2018-09-06	Iniziato	Credit Suisse	Outperform
2018-08-01	Aggiornamento	Morgan Stanley	Equal-Weight → Overweight
2018-06-21	Reiterato	Robert W. Baird	Outperform
2018-06-20	Reiterato	Needham	Buy
2018-06-19	Reiterato	H.C. Wainwright	Buy

Mostra tutto

Sarepta Therapeutics Inc Borsa (SRPT) Ultime notizie

03:10 AM

683 Capital Management LLC Grows Stock Position in Sarepta Therapeutics, Inc. $SRPT - MarketBeat

03:10 AM

Dec 12, 2025

Sarepta Therapeutics (NASDAQ:SRPT) Shares Gap DownHere's What Happened - MarketBeat

Dec 12, 2025

Mizuho reiterates Outperform rating on Sarepta stock amid debt refinancing - Investing.com

Dec 11, 2025

Mizuho reiterates Outperform rating on Sarepta stock amid debt refinancing By Investing.com - Investing.com UK

Dec 11, 2025

Sarepta Therapeutics stock falls after debt exchange announcement - Investing.com

Dec 11, 2025

Why Is SRPT Stock Falling Today? - Stocktwits

Dec 11, 2025

Sector Update: Health Care Stocks Mixed Premarket Thursday - marketscreener.com

Dec 11, 2025

Sarepta dips after announcing debt refinancing - TradingView

Dec 11, 2025

Sarepta Therapeutics stock falls after refinancing of convertible notes By Investing.com - Investing.com South Africa

Dec 11, 2025

Sarepta to refinance $291M of existing notes due 2027 - MSN

Dec 11, 2025

Sarepta Therapeutics Refinances $291 Million in Convertible Senior Notes Due 2027 - marketscreener.com

Dec 11, 2025

Sarepta to exchange $291.4 million in convertible notes - Investing.com

Dec 11, 2025

Sarepta Therapeutics Announces Refinancing of Approximately $291 Million of 1.25% Convertible Senior Notes due 2027 - Business Wire

Dec 11, 2025

Dec 10, 2025

Sarepta Therapeutics' Myotonic Dystrophy Type 1 Trial Data Could Boost Investor Sentiment, Oppenheimer Says - marketscreener.com

Dec 10, 2025

United States Gene Therapy Market to Hit $6510.45 Million by 2033 - openPR.com

Dec 10, 2025